Mead Johnson Nutrition CO (MJN) was Upgraded by CLSA to ” Outperform” and the brokerage firm has set the Price Target at $96. Earlier the firm had a rating of “Underperform ” on the company shares. CLSA advised their investors in a research report released on Aug 3, 2016.
Many Wall Street Analysts have commented on Mead Johnson Nutrition CO. Mead Johnson Nutrition CO was Downgraded by Societe Generale to ” Hold” on Jul 29, 2016. Mead Johnson Nutrition CO was Upgraded by JP Morgan to ” Overweight” on Jul 26, 2016. Mead Johnson Nutrition CO was Upgraded by BofA/Merrill to ” Neutral” on Jul 13, 2016.
On the company’s financial health, Mead Johnson Nutrition CO reported $0.88 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $0.78. The company had revenue of $941.50 million for the quarter, compared to analysts expectations of $963.64 million. The company’s revenue was down -8.8 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.76 EPS.
Mead Johnson Nutrition CO closed down -0.43 points or -0.49% at $87.29 with 19,18,520 shares getting traded on Tusday. Post opening the session at $87.7, the shares hit an intraday low of $85.79 and an intraday high of $87.79 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.
In a different news, on May 3, 2016, Christoper Richard Stratton (SVP and President, Asia) sold 33,730 shares at $86.68 per share price. According to the SEC, on Dec 14, 2015, Michel Martinus Gerardus Cup (CFO) purchased 4,000 shares at $76.50 per share price. On Nov 25, 2015, Robert S Singer (director) sold 4,000 shares at $81.77 per share price, according to the Form-4 filing with the securities and exchange commission.
Mead Johnson Nutrition Company (Mead Johnson) is a global pediatric nutrition company. The Company manufactures distributes and sells infant formulas children’s nutrition and other nutritional products. Its product portfolio includes routine and specialty infant formulas childrens milks and milk modifiers dietary supplements for pregnant and breastfeeding mothers pediatric vitamins and products for pediatric metabolic disorders. The Company operates through three segments: Asia Latin America and North America/Europe. The Company’s Enfa family of brands including Enfamil infant formula is a brand franchise in pediatric nutrition. Its product portfolio addresses a range of nutritional needs for infants children and expectant and nursing mothers. The Company markets its portfolio of more than 70 products to mothers healthcare professionals and retailers in more than 50 countries in Asia North America Latin America and Europe.